Page last updated: 2024-08-26

fotemustine and Melanoma

fotemustine has been researched along with Melanoma in 141 studies

*Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) [MeSH]

Research

Studies (141)

TimeframeStudies, this research(%)All Research%
pre-19902 (1.42)18.7374
1990's65 (46.10)18.2507
2000's44 (31.21)29.6817
2010's27 (19.15)24.3611
2020's3 (2.13)2.80

Authors

AuthorsStudies
Bonnet, PA; Bressolle, F; David, N; Deleuze-Masquefa, C; Gayraud-Paniagua, S; Khier, S; Moarbess, G; Pinguet, F1
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM1
Alamodi, A; Gomez, CR; Grada, Z; Haikel, Y; Hassan, M; Hassan, SL; Hassan, SY; Jamal, SME; Megahed, M; Murad, F; Santourlidis, S; Shareef, MA; Wahl, RU1
Bauer, S; Haubold, J; Ludwig, JM; Richly, H; Schaarschmidt, BM; Siveke, JT; Theysohn, JM; Umutlu, L; Wimmer, J1
Amato, G; Calabrò, L; Camerini, R; Chiarion-Sileni, V; Covre, A; Cutaia, O; Del Vecchio, M; Di Giacomo, AM; Ferrucci, PF; Giannarelli, D; Guida, M; Guidoboni, M; Maio, M; Mandalà, M; Marchetti, P; Quaglino, P; Valente, M1
Aprea, P; Ascierto, PA; Botti, G; Caracò, C; Cavalcanti, E; Comella, G; Cossu, A; Daponte, A; Gallo, C; Grimaldi, AM; Lastoria, S; Maiorino, L; Massidda, B; Mozzillo, N; Palmieri, G; Petrillo, A; Signoriello, S; Simeone, E1
Addeo, R; Caraglia, M; Facchini, S; Luce, A; Zappavigna, S1
Grosso, M; Pesce, M; Picasso, V; Queirolo, P; Spagnolo, F; Tornari, E1
Berniard, A; Carita, G; de Montrion, C; de Plater, L; Decaudin, D; Depil, S; Desjardins, L; Geneste, O; Kraus-Berthier, L; Lang, G; Lockhart, B; Némati, F; Pierré, A; Piperno-Neumann, S; Sastre-Garau, X; Vallerand, D1
Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L1
Baurain, JF; Durando, X; Gurunath, RK; Jouary, T; Kaempgen, E; Keilholz, U; Leyvraz, S; Marshall, E; Negrier, S; Piperno-Neumann, S; Schadendorf, D; Scheulen, M; Suciu, S; Testori, A; Vermorken, JB; Zdzienicki, M1
Aigner, B; Artl, M; Niederkorn, A; Richtig, E; Schwantzer, G; Wackernagel, W1
Annesi, D; Ascierto, PA; Calabrò, L; Danielli, R; Del Vecchio, M; Di Giacomo, AM; Fonsatti, E; Giannarelli, D; Guidoboni, M; Maccalli, C; Maio, M; Maurichi, A; Orgiano, L; Parmiani, G; Pilla, L; Queirolo, P; Ridolfi, R; Santinami, M; Simeone, E; Spadola, G; Testori, A1
Christmann, M; Kaina, B; Krumm, A; Loquai, C; Merz, S; Quiros, S; Roos, WP; Switzeny, OJ1
Chi, ZH; Cui, CL; Guo, J; Lian, HY; Si, L; Yuan, XQ1
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I1
Aitini, E; Ballardini, M; Bichisao, E; Fiorentini, G; Freschi, A; Guida, M; Michiara, M; Ridolfi, L; Ridolfi, R1
Cuttone, G; Iannolo, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Valastro, LM; Zakula, JJ1
Ferri-Níguez, B; González-Tortosa, J; Ros de San Pedro, J1
Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; Gattacceca, F; Khier, S; Margout, D; Moarbess, G; Pinguet, F; Solassol, I1
Bechrakis, N; Foerster, MH; Keilholz, U; Krössin, M; Lindner, M; Schmittel, A; Schuster, R; Thiel, E; Wacker, F1
Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S1
Anichini, A; Bajetta, E; Bedognetti, D; Canova, S; Del Vecchio, M; Di Guardo, L; Morosini, P; Mortarini, R; Perrone, T; Pimpinelli, N; Queirolo, P; Sertoli, MR1
Colucci, G; Cramarossa, A; Fistola, E; Giudice, G; Guida, M; Lubello, K; Porcelli, M1
Di Giacomo, AM; Maio, M; Margolin, KA1
Anastassiou, G; Bornfeld, N; Freistuehler, M; Hilger, RA; Nareyeck, G; Scheulen, ME; Steuhl, KP; Westekemper, H; Zeschnigk, M1
Cuttone, G; Iannolo, G; Keta, O; Korićanac, L; Petrović, I; Ristić-Fira, A; Žakula, J1
Amadori, D; Calzolari, F; Farolfi, A; Guidoboni, M; Milandri, C; Ridolfi, L; Ridolfi, R; Scarpi, E1
Dréno, B; Quéreux, G1
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A1
Auffret, M; Bertrand, M; Gauthier, S; Mortier, L; Wémeau-Stervinou, L1
Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E1
Annesi, D; Ascierto, PA; Di Giacomo, AM; Ferrucci, PF; Fonsatti, E; Giannarelli, D; Maio, M; Marasco, A; Nicoletti, SV; Parmiani, G; Pilla, L; Queirolo, P; Ridolfi, R; Rivoltini, L; Santinami, M; Simeone, E; Testori, A1
Garbe, C1
Beitzke, D; Berzaczy, D; Edelhauser, G; Funovics, M; Höeller, C; Lammer, J; Schicher, N1
Campello, C; Meunier, L; Renard, D; Stoebner, P1
Geissler, A; Gruss, C; Landthaler, M; Schalke, B; Stolz, W1
Foletto, M; Lise, M; Mocellin, S; Pilati, P; Rossi, CR1
Becker, JC; Bröcker, EB; Kämpgen, E; Lieb, W; Neumann, C; Schadendorf, D; Steinmann, A; Terheyden, P; Wagner, S; Wittenberg, G1
Aglione, S; Bajetta, E; Bernard-Marty, C; Buzzoni, R; Del Vecchio, M; Khayat, D; Nova, P; Rixe, O; Taillibert, S; Vitali, M1
Gschwendt, B; Helmbach, H; Kioschis, P; Korn, B; Lichter, P; Mollenhauer, J; Münstermann, E; Nessling, M; Poustka, A; Salowsky, R; Schadendorf, D; Schick, M; Will, RD; Wittig, R1
Bensadoun, RJ; Bonneterre, ME; Bourdin, S; Bui, BN; Clavel, M; Cupissol, D; De Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Thomas, L; Tilgen, W; Ulrich, J1
Dréno, B; Wallon-Dumont, G1
Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH1
Bensadoun, JR; Bonneterre, J; Bourdin, S; Clavel, M; Cupissol, D; de Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Nguyen, BB; Thomas, L; Tilgen, W; Ulrich, J1
Bouissière, JL; Cuq, P; Evrard, A; Montero, JL; Montero, V; Passagne, I; Winum, JY1
De Salvo, GL; Foletto, M; Lejeune, FJ; Lise, M; Lopes, M; Mocellin, S; Pilati, PL; Pontes, L; Ribeiro, M; Rossi, CR1
Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Montero, JL; Passagne, I; Vian, L; Winum, JY1
Aamdal, S; Avril, MF; Bieber, T; Bonerandi, JJ; Bonneterre, J; Fra, J; Gilde, K; Gonzalez Larriba, JL; Grob, JJ; Guillem Porta, V; Hauschild, A; Kamanabrou, D; Menu, Y; Mohr, P; Neuber, K; Pehamberger, H; Saïag, P; Scherrer, A; Sufliarsky, J; Weichenthal, M1
Eigentler, TK; Garbe, C1
Friedlander, M; Kurtovic, J; Riordan, SM; Singh-Grewal, I; Webster, GJ1
Bonenkamp, JJ; de Faria Lima, R; de Wilt, JH; Doubrovsky, A; Kam, PC; Thompson, JF1
Grange, JD; Kodjikian, L; Rivoire, M1
Acquati, M; Eggermont, AM; Kirkwood, JM; Queirolo, P; Rocca, A; Testori, A1
Karpenko, LG1
Carlander, B; Guillot, B; Khalil, Z; Pageot, N1
Bosshard, W; Fiorentini, G; Gillet, M; Humblet, Y; Keilholz, U; Leyvraz, S; Lotem, M; Pampallona, S; Peters, S; Piperno-Neumann, S; Popescu, R; Stupp, R; Voelter, V; Weitzen, R; Zografos, L1
Akimov, MA; Bogdanova, NV; Gershanovich, ML; Konstantinova, MM; Nosov, DA1
Clerico, MA; Marinozzi, C; Sozzi, P; Turrisi, G1
Bembenek, A; Hauschild, A; Kähler, KC; Kettelhack, C; Schlag, PM; Siegel, R1
Cuttone, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Todorović, DV; Valastro, LM1
Amadori, D; Bonafe, M; Brigliadori, G; Fabbri, F; Rosetti, M; Storci, G; Tesei, A; Ulivi, P; Vannini, I; Zoli, W1
Bajetta, E; Canova, S; Del Vecchio, M; Messina, A1
Gill, S; Prince, HM; Shapiro, J; Westerman, D1
Camlica, H; Tas, F; Topuz, E1
Avril, MF1
Denys, A; Goitein, G; Halkic, N; Leyvraz, S; Pampallona, S; Peters, S; Schalenbourg, A; Voelter, V; Zografos, L1
Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M1
Bröcker, EB; Engel, E; Gérard, B; Glabbeke, MV; Israels, P; Kennes, C; Kleeberg, UR; Lejeune, F; Lentz, MA; Tilgen, W1
Barbé, V; Berlion, M; Berrile, J; Bizzari, JP; Fischel, JL; Formento, P; Milano, G2
Gerard, B; Punt, CJ; Tytgat, JH; van Liessum, PA1
A'Hern, R; Atkinson, H; Chang, J; Gore, ME; Lorentzos, A1
Falkson, CI; Falkson, G; Falkson, HC1
Berille, J; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Giroux, B; Khayat, D; Sarkany, M1
Boaziz, C; Breau, JL; Israël, L; Mazeron, JJ; Morere, JF1
Bureau, B; Célérier, P; Dreno, B; Litoux, P1
Chaitchik, S; Merimsky, O1
Aliaga, A; Bizzari, JP; Cour, V; Lopez Lopez, JJ; Oliver, V; Perez, E; Ponchon, A1
Dougal, M; Lee, SM; Margison, GP; Thatcher, N1
Aamdal, S; Bizzari, JP; D'Incalci, M; Gerard, B; Lee, SM; Leyvraz, S; Lucas, C1
Lee, SM; Margison, GP; Thatcher, N; Woodcock, AA1
Antoine, E; Auclerc, G; Benhammouda, A; Bizzari, JP; Borel, C; Paraiso, D; Petit, T; Rixe, O; Soubrane, C; Weil, M1
Avril, MF; Borel, C; Giroux, B; Khayat, D; Monnier, A; Petit, T; Rixe, O; Weil, M1
Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL1
Anderson, CM; Buzaid, AC; Legha, SS1
Bohndorf, W; Bröcker, EB; Engenhart, K; Flentje, M; Kämpgen, E; Messer, P; Tilgen, W; Trcka, J1
Bauer, J; Dorval, T; Gillet, M; Lejeune, F; Leyvraz, S; Meuli, R; Pampallona, S; Salmon, R; Spataro, V; Zografos, L1
Bartley, J; Eaglesham, GK; Hayes, MT; Parsons, PG; Prakash, AS1
Caponigro, F; Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Ionna, F; Mozzillo, N; Parziale, AP; Presutti, F1
Azevedo, MC; Lopes, M; Pontes, L; Ribeiro, M; Santos, JG1
Altenhoff, J; Breitbart, EW; Hossfeld, DK; Kowalzick, L; Marseille, A; Mohr, P; Sarkany, M; Stephan, U; Weichenthal, M1
Bartley, J; Hayes, MT; Parsons, PG1
Asselain, B; Desjardins, L; Dorval, T; Levy, C; Leyvraz, S; Plancher, C; Pouillart, P; Salmon, RJ; Schlienger, P; Servois, V1
Breitbart, E; Makki, A; Mohr, P; Schadendorf, D1
Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H1
Casella, G; di Bonito, M; Fortuna, G; Iodice, F; Stellato, G; Tramontana, R; Tramontana, S1
Bröcker, EB; Göring, HD; Kämpgen, E; Kröning, Y; Trebing, D; Zierner, A1
Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F1
Bonerandi, JJ; Delaunay, M; Grob, JJ; Koeppel, MC; Laurans, R; Murraciole, X; Paul, K; Perragut, JC; Regis, J; Souteyrand, P; Wolkenstein, P1
Becker, JC; Bröcker, EB; Kämpgen, E; Rünger, TM; Terheyden, P1
Aamdal, S; Bohmann, T; Gerard, B; Lucas, C; Semb, KA1
Ablett, E; Dannoy, PA; Parsons, PG; Pedley, J; Sturm, RA1
Christmann, M; Dietel, M; Kaina, B; Kern, MA; Lage, H; Pick, M; Schadendorf, D1
Binder, M; Pehamberger, H; Seeber, A; Steiner, A; Wolff, K1
Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D1
Comella, P; Daponte, A1
Gademann, G; Gollnick, H; Ulrich, J1
Diem, C; Emmert, S; Epe, B; Hellfritsch, D; Rünger, TM; Schadendorf, D1
Kern, MA; Lichter, P; Nessling, M; Schadendorf, D1
Becker, JC; Bröcker, EB; Kämpgen, E; Terheyden, P1
Ascierto, PA; Cellerino, R; Comella, G; Comella, P; Daponte, A; DeLena, M; Gravina, A; Marini, G; Melucci, MT; Palmieri, G1
Bock, M; Deichmann, M; Jäckel, A; Näher, H; Waldmann, V1
Christmann, M; Kaina, B; Lage, H; Pick, M; Schadendorf, D1
Egerer, G; Ho, AD; Keilholz, U; Lehnert, T; Max, R; Naeher, H1
Berlion, M; Marchal, S; Merlin, JL; Poullain, MG; Ramacci, C1
Chaitchik, S; Inbar, M; Kovner, F; Merimsky, O; Reider-Groswasser, I1
Chaitchik, S; Gerard, B; Inbar, M; Merimsky, O1
Elgren, TE; Hogenkamp, HP; MacFarlan, S; Nelson, LS; Schallreuter, KU; Yan-Sze, I1
Boaziz, C1
Avril, MF; Bonneterre, J; Cupissol, D; Fargeot, P; Fumoleau, P; Grob, JJ; Israel, L; Kalis, B; Kerbrat, P; Lambert, D1
Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K1
Avril, MF; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Khayat, D1
Chaitchik, S; Inbar, M; Merimsky, O1
Aamdal, S; Bohman, T; D'Incalci, M; Gerard, B1
Ring, J; Schallreuter, KU1
Berger, J; Brassow, FW; Breitbart, EW; Schallreuter, KU; Teichmann, W; Wenzel, E1
Breitbart, EW; Mensing, H; Schallreuter, KU; Wood, JM1
Lee, SM; Margison, GP; Thatcher, N1
Chaitchik, S; Inbar, M; Merimsky, O; Reider-Groswasser, I1
Boaziz, C; Breau, JL; Israël, L; Morere, JF1
Aigner, K; Auclerc, G; Bizzari, JP; Borel, C; Bousquet, JC; Buthiau, D; Cohen-Alloro, G; Cour, V; Khayat, D; Weil, M1
Aapro, M; Ardizzoni, A; Becquart, D; Calabresi, F; Dirix, L; Gerard, B; Wils, J1
Schallreuter, KU; Wood, JM1
Avril, MF; Banzet, P; Bonerandi, JJ; Bonneterre, J; Fumoleau, P; Jacquillat, C; Kerbrat, P; Khayat, D; Namer, M; Weil, M2
Avril, MF; Bonneterre, J; Bugat, R; Cupissol, D; Delaunay, M; Fumoleua, P; Grosshans, E; Israel, L; Kerbrat, P; Namer, M1
Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G1
Beerblock, K; Bizzari, JP; Deloffre, P; Lokiec, F; Lucas, C1
Banzet, P; Bizzari, JP; Frenay, M; Goupil, A; Jacquillat, C; Khayat, D; Naman, H; Namer, M; Rouesse, J; Weil, M1

Reviews

20 review(s) available for fotemustine and Melanoma

ArticleYear
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 123

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib

2019
Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.
    Expert opinion on drug safety, 2013, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

2013
[Cerebellopontine angle meningeal melanocytoma: a benign tumor?].
    Neurocirugia (Asturias, Spain), 2009, Volume: 20, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Cerebellopontine Angle; Diagnosis, Differential; Disease Progression; Fatal Outcome; Gait Disorders, Neurologic; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neurilemmoma; Nevus; Nitrosourea Compounds; Organophosphorus Compounds

2009
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
    Seminars in oncology, 2010, Volume: 37, Issue:5

    Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Italy; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Temozolomide; United States

2010
Fotemustine for the treatment of melanoma.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:18

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Melanoma; Molecular Structure; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome

2011
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
    Bulletin du cancer, 2013, Jan-01, Volume: 100, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib

2013
Isolated limb perfusion in locally advanced cutaneous melanoma.
    Seminars in oncology, 2002, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Genetic Therapy; Humans; Melanoma; Melphalan; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Reproducibility of Results; Skin Neoplasms; Tumor Necrosis Factor-alpha

2002
Metastatic melanoma: chemotherapy.
    Seminars in oncology, 2002, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Cytokines; Dacarbazine; Genetic Therapy; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Tamoxifen; Taxoids; Thalidomide

2002
[Treatment of melanoma].
    Presse medicale (Paris, France : 1983), 2003, Jan-11, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Forecasting; Humans; Immunization, Passive; Immunotherapy; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Temozolomide; Time Factors

2003
[Therapy of malignant melanoma at the stage of distant metastasis].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine

2004
Update: current management issues in malignant melanoma.
    Melanoma research, 2005, Volume: 15, Issue:5

    Topics: Chemotherapy, Adjuvant; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

2005
Fotemustine in the treatment of brain primary tumors and metastases.
    Cancer investigation, 1994, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Glioma; Humans; Lung Neoplasms; Melanoma; Middle Aged; Multicenter Studies as Topic; Nitrosourea Compounds; Organophosphorus Compounds

1994
[Malignant melanoma of the uvea].
    Bulletin du cancer, 1993, Volume: 80, Issue:7

    Topics: Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Eye Enucleation; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Uveal Neoplasms

1993
Systemic treatments for advanced cutaneous melanoma.
    Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide

1995
[Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1998, Volume: 49, Issue:10

    Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Treatment Outcome; Uveal Neoplasms

1998
[Therapy of metastatic malignant uveal melanoma].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2001, Volume: 52, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoembolization, Therapeutic; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Skin Neoplasms; Time Factors; Uveal Neoplasms

2001
[Contribution of a new nitrosourea compound: fotemustine].
    Pathologie-biologie, 1992, Volume: 40, Issue:9 Pt 2

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dacarbazine; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

1992
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Melanoma research, 1992, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine

1992
[Brain metastases of malignant melanomas].
    Bulletin du cancer, 1991, Volume: 78, Issue:4

    Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Semustine

1991
Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction

1991

Trials

45 trial(s) available for fotemustine and Melanoma

ArticleYear
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 09-01, Volume: 27, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Time Factors; Young Adult

2021
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
    Journal of translational medicine, 2013, Feb-13, Volume: 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Analysis

2013
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:3

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Uveal Neoplasms; Young Adult

2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Brain Neoplasms; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Skin Neoplasms; Survival Rate

2015
[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
    Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokine-Induced Killer Cells; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatic Artery; Humans; Immunotherapy, Adoptive; Infusions, Intra-Arterial; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Survival Rate; Thrombocytopenia; Young Adult

2008
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Melanoma research, 2009, Volume: 19, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Salvage Therapy; Skin Neoplasms; Survival Analysis

2009
Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Dec-01, Volume: 16, Issue:23

    Topics: Adult; Aged; Angiogenic Proteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cells, Cultured; Female; Humans; Lymphangiogenesis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Young Adult

2010
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Hematologic Diseases; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

2012
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
    British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Hepatic Artery; Humans; Immunotherapy; Infusions, Intra-Arterial; Interferon-alpha; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Rate; Treatment Outcome; Uveal Neoplasms

2002
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
    Melanoma research, 2003, Volume: 13, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome

2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003, Volume: 7, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Female; Humans; Life Tables; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome

2003
Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.
    Melanoma research, 2003, Volume: 13, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome

2003
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-15, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Skin Neoplasms; Statistics, Nonparametric; Survival Analysis

2004
[Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)].
    Voprosy onkologii, 2005, Volume: 51, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Tamoxifen; Treatment Outcome

2005
Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2007, Volume: 33, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Eye Neoplasms; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Analysis

2007
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide

2008
Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
    Melanoma research, 2008, Volume: 18, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Risk; Secondary Prevention; Survival Analysis; Uveal Neoplasms

2008
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG).
    Melanoma research, 1995, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Treatment Outcome

1995
Fotemustine and tamoxifen combination therapy in metastatic malignant melanoma. A phase II study.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Tamoxifen

1995
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Outcome

1994
Phase II trial of fotemustine in patients with metastatic malignant melanoma.
    Investigational new drugs, 1994, Volume: 12, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Failure

1994
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
    British journal of cancer, 1993, Volume: 67, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome; Thrombocytopenia

1993
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
    Melanoma research, 1995, Volume: 5, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine

1995
Complete remission seven years after treatment for metastatic malignant melanoma.
    Cancer, 1996, Mar-01, Volume: 77, Issue:5

    Topics: Antineoplastic Agents; Disease-Free Survival; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Splenic Neoplasms

1996
Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study.
    Melanoma research, 1996, Volume: 6, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Radiotherapy Dosage; Treatment Outcome

1996
Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Catheters, Indwelling; Eye Neoplasms; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome

1997
Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Rate

1997
Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
    Melanoma research, 1997, Volume: 7, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms

1997
Fotemustine and interferon alpha2b in metastatic malignant melanoma.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Treatment Outcome

1998
Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
    Melanoma research, 1998, Volume: 8, Issue:2

    Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Drug Administration Schedule; Humans; Leukopenia; Melanoma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms; Thrombocytopenia

1998
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
    Melanoma research, 1998, Volume: 8, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen

1998
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Glioma; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide

1998
Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma.
    Melanoma research, 1998, Volume: 8, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Tamoxifen; Time Factors

1998
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide

1999
Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
    Melanoma research, 2000, Volume: 10, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Skin Neoplasms; Survival Rate

2000
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Cancer, 2000, Dec-15, Volume: 89, Issue:12

    Topics: Adult; Aged; Anemia; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Dacarbazine; Female; Fever; Follow-Up Studies; Humans; Interferon-alpha; Male; MART-1 Antigen; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Nausea; Neoplasm Proteins; Neural Cell Adhesion Molecules; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting

2000
Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients.
    International journal of clinical oncology, 2001, Volume: 6, Issue:1

    Topics: Adult; Antineoplastic Agents; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Treatment Outcome; Uveal Neoplasms

2001
Fotemustine--an advance in the treatment of metastatic malignant melanoma.
    Melanoma research, 1992, Volume: 2, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

1992
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Melanoma research, 1992, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine

1992
Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
    American journal of clinical oncology, 1992, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Remission Induction

1992
Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction

1991
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

1991
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
    Cancer, 1990, Nov-01, Volume: 66, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds

1990
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
    Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds

1990
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
    Cancer chemotherapy and pharmacology, 1990, Volume: 25, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Tomography, X-Ray Computed

1990

Other Studies

78 other study(ies) available for fotemustine and Melanoma

ArticleYear
New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:9

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Quinoxalines; Structure-Activity Relationship

2009
Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways.
    Oncogene, 2020, Volume: 39, Issue:32

    Topics: AC133 Antigen; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Stem Cells

2020
Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion.
    Radiology and oncology, 2021, May-31, Volume: 55, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Biomarkers, Tumor; Blood Platelets; C-Reactive Protein; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocytes; Male; Melanoma; Melphalan; Middle Aged; Neutrophils; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Tumor Burden; Uveal Neoplasms

2021
Treatment of metastatic uveal melanoma with intravenous fotemustine.
    Melanoma research, 2013, Volume: 23, Issue:3

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Rate; Treatment Outcome; Uveal Neoplasms

2013
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Proliferation; Fluorescence Polarization; Heterocyclic Compounds, 3-Ring; Humans; Immunohistochemistry; Melanoma; Mice; Mice, SCID; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Nitrosourea Compounds; Organophosphorus Compounds; Peptides; Protein Binding; Sulfonamides; Survival Analysis; Uveal Neoplasms; Xenograft Model Antitumor Assays

2014
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
    Annales de dermatologie et de venereologie, 2014, Volume: 141, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib

2014
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
    Acta ophthalmologica, 2014, Volume: 92, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Uveal Neoplasms

2014
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
    Oncotarget, 2014, Dec-30, Volume: 5, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Humans; Indoles; Melanoma; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Sulfonamides; Temozolomide; Vemurafenib

2014
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:8

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib

2009
Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.
    Journal of experimental & clinical cancer research : CR, 2009, Apr-09, Volume: 28

    Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Protons

2009
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2010, Jan-31, Volume: 39, Issue:1-3

    Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Imiquimod; Injections, Intraperitoneal; Injections, Intravenous; Male; Melanoma; Mice; Mice, Nude; Nitrosourea Compounds; Organophosphorus Compounds; Quinoxalines; Rats; Skin Neoplasms; Xenograft Model Antitumor Assays

2010
Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
    Melanoma research, 2010, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoembolization, Therapeutic; Cisplatin; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome; Uveal Neoplasms

2010
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Apr-15, Volume: 16, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Mice; Mice, SCID; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Oligonucleotide Array Sequence Analysis; Organophosphorus Compounds; Polymorphism, Single Nucleotide; Temozolomide; Tumor Cells, Cultured; Uveal Neoplasms; Xenograft Model Antitumor Assays

2010
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
    Journal of translational medicine, 2010, Nov-10, Volume: 8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide

2010
Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents.
    International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Conjunctival Neoplasms; Humans; Melanoma; Mitomycin; Nitrosourea Compounds; Organophosphorus Compounds; Tretinoin

2011
Proton inactivation of melanoma cells enhanced by fotemustine.
    Radiation protection dosimetry, 2011, Volume: 143, Issue:2-4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Proton Therapy; Radiation Tolerance; Radiotherapy, Conformal

2011
Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study.
    Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Drug Delivery Systems; Drug Monitoring; Electronic Health Records; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis; Uveal Neoplasms; Young Adult

2011
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
    Experimental dermatology, 2011, Volume: 20, Issue:12

    Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome

2011
[New toxicity of fotemustine: diffuse interstitial lung disease].
    Annales de dermatologie et de venereologie, 2012, Volume: 139, Issue:4

    Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lung Diseases, Interstitial; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

2012
Ipilimumab with fotemustine in metastatic melanoma.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Ipilimumab; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

2012
Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis.
    AJR. American journal of roentgenology, 2012, Volume: 199, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Chemoembolization, Therapeutic; Contrast Media; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Uveal Neoplasms

2012
Fotemustine-related leukoencephalopathy.
    Acta neurologica Belgica, 2013, Volume: 113, Issue:3

    Topics: Aged; Antineoplastic Agents; Brain; Female; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Tomography Scanners, X-Ray Computed

2013
Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation.
    Melanoma research, 2002, Volume: 12, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Atrophy; Brain; Brain Damage, Chronic; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dementia; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Quality of Life; Radiotherapy, High-Energy; Remission Induction

2002
Candidate genes for cross-resistance against DNA-damaging drugs.
    Cancer research, 2002, Nov-15, Volume: 62, Issue:22

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Cisplatin; Cluster Analysis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Tumor Cells, Cultured

2002
Topical imiquimod in the treatment of metastatic melanoma to skin.
    Archives of dermatology, 2003, Volume: 139, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome

2003
Synthesis and biological evaluation of Fotemustine analogues on human melanoma cell lines.
    European journal of medicinal chemistry, 2003, Volume: 38, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, Thin Layer; Colony-Forming Units Assay; Coloring Agents; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Magnetic Resonance Spectroscopy; Melanoma; Neutral Red; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds

2003
Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 307, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Carmustine; DNA Damage; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Guanine; Humans; Melanoma; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Tumor Cells, Cultured

2003
Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment.
    Internal medicine journal, 2004, Volume: 34, Issue:5

    Topics: Acetylcysteine; Adult; Antineoplastic Agents; Antioxidants; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Treatment Outcome

2004
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2004, Volume: 30, Issue:10

    Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Follow-Up Studies; Humans; Limb Salvage; Lower Extremity; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome

2004
Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2005, Volume: 243, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Fatal Outcome; Female; Follow-Up Studies; Hepatectomy; Humans; Injections, Intra-Arterial; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Time Factors; Uveal Neoplasms

2005
[Experience with use of mustoforan at the Clinical Oncological Dispensary of the Republic of Tatarstan].
    Voprosy onkologii, 2005, Volume: 51, Issue:3

    Topics: Antineoplastic Agents; Cancer Care Facilities; Disease Progression; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Russia; Skin Neoplasms; Treatment Outcome

2005
Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Melanoma research, 2005, Volume: 15, Issue:6

    Topics: Antineoplastic Agents; Brain Neoplasms; Female; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds

2005
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Uveal Neoplasms

2006
Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Melanoma research, 2006, Volume: 16, Issue:6

    Topics: Aged; Antineoplastic Agents; Humans; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia

2006
Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
    Annals of the New York Academy of Sciences, 2007, Volume: 1095

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Proton Therapy

2007
Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine.
    Cellular oncology : the official journal of the International Society for Cellular Oncology, 2007, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Cisplatin; DNA Mutational Analysis; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Tumor Suppressor Protein p53

2007
Impressive objective response in a patient with extensive metastatic melanoma including the brain.
    Melanoma research, 2007, Volume: 17, Issue:5

    Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Female; Humans; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed

2007
Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-01, Volume: 25, Issue:28

    Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Tomography, X-Ray Computed

2007
[Fotemustine: muphoran].
    Annales de dermatologie et de venereologie, 2007, Volume: 134, Issue:12

    Topics: Antineoplastic Agents; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

2007
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
    Cancer, 1994, Jan-01, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine

1994
[Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
    Bulletin du cancer, 1994, Volume: 81, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; In Vitro Techniques; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured

1994
Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured

1993
[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Annales de dermatologie et de venereologie, 1993, Volume: 120, Issue:6-7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome

1993
Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

1993
Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction

1993
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
    British journal of cancer, 1993, Volume: 67, Issue:2

    Topics: Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Humans; Leukocytes, Mononuclear; Melanoma; Methyltransferases; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds

1993
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Lung; Lung Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome

1993
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Annales de dermatologie et de venereologie, 1995, Volume: 122, Issue:10

    Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

1995
Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity.
    Biochemistry, 1997, Sep-02, Volume: 36, Issue:35

    Topics: Antineoplastic Agents; Cell Survival; DNA Adducts; DNA Methylation; DNA Repair; Dose-Response Relationship, Drug; Drug Stability; Guanine; HeLa Cells; Humans; Mass Spectrometry; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Tumor Cells, Cultured

1997
In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma.
    Melanoma research, 1998, Volume: 8, Issue:1

    Topics: Adenoviridae; Antineoplastic Agents; Carcinogens; Cell Cycle; Cell Survival; DNA, Neoplasm; Drug Evaluation; Humans; Hyperthermia, Induced; Melanoma; Methylnitronitrosoguanidine; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Perfusion; Skin Neoplasms; Tumor Cells, Cultured; Virus Replication

1998
Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1998, Volume: 24, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome; Uveal Neoplasms

1998
Primary malignant melanoma of the vagina: case report.
    European journal of gynaecological oncology, 1998, Volume: 19, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lymph Node Excision; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Vaginal Neoplasms

1998
Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
    Melanoma research, 1998, Volume: 8, Issue:4

    Topics: Allergens; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dermatitis, Allergic Contact; Dinitrochlorobenzene; Humans; Immunotherapy; Irritants; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms

1998
Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancérologie Cutanée.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

1998
UVB-specific regulation of gene expression in human melanocytic cells: cell cycle effects and implication in the generation of melanoma.
    Mutation research, 1998, Nov-09, Volume: 422, Issue:1

    Topics: Antineoplastic Agents; beta-Galactosidase; Cell Cycle; Cisplatin; Demecolcine; Genes, fos; Genes, p53; HeLa Cells; HIV Long Terminal Repeat; Humans; Hydroxyurea; Inosine; Melanocytes; Melanoma; Methylnitronitrosoguanidine; Neoplasms, Radiation-Induced; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins c-fos; Recombinant Proteins; Skin Neoplasms; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured; Ultraviolet Rays

1998
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
    International journal of cancer, 1999, Mar-01, Volume: 80, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carrier Proteins; Cisplatin; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; Drug Resistance, Multiple; Etoposide; Humans; Melanoma; MutL Protein Homolog 1; MutS Homolog 2 Protein; N-Glycosyl Hydrolases; Neoplasm Proteins; Nitrosourea Compounds; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins; RNA, Messenger; Transcription, Genetic; Vindesine

1999
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome

1998
Comments on: Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine, Seeber, et al., Eur J Cancer 1998, 34, 2129-2131.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

1999
Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
    Journal of neuro-oncology, 1999, Volume: 43, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis

1999
Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
    The Journal of investigative dermatology, 2000, Volume: 114, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; DNA Repair; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Melanoma; Microsatellite Repeats; Nitrosourea Compounds; Organophosphorus Compounds; Oxygen; Tumor Cells, Cultured; Ultraviolet Rays

2000
Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines.
    Cytogenetics and cell genetics, 1999, Volume: 87, Issue:3-4

    Topics: Aneuploidy; Antineoplastic Agents; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 9; Cisplatin; DNA Mutational Analysis; DNA Probes; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Etoposide; Genome, Human; Humans; Melanoma; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Selection, Genetic; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Vindesine

1999
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
    International journal of cancer, 2001, Apr-01, Volume: 92, Issue:1

    Topics: Antineoplastic Agents; Azacitidine; Blotting, Southern; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Enzyme Reactivators; Gene Amplification; Gene Expression; Guanine; Humans; Melanoma; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Promoter Regions, Genetic; Tumor Cells, Cultured

2001
Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
    Anti-cancer drugs, 2002, Volume: 13, Issue:2

    Topics: Amifostine; Antineoplastic Agents; Cell Survival; Drug Synergism; Humans; Inhibitory Concentration 50; Melanoma; Mercaptoethylamines; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Radiation-Protective Agents; Tumor Cells, Cultured

2002
Cerebral metastatic melanoma: correlation between clinical and CT findings.
    Melanoma research, 1992, Volume: 2, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed

1992
Ribonucleotide diphosphate reductase from human metastatic melanoma.
    Melanoma research, 1992, Volume: 2, Issue:5-6

    Topics: Antineoplastic Agents; Cell-Free System; Electron Spin Resonance Spectroscopy; Humans; Hydroxyurea; Kinetics; Macromolecular Substances; Melanoma; Models, Structural; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Ribonucleoside Diphosphate Reductase

1992
Fotemustine plus dacarbazine for malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia

1992
Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia

1992
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28, Issue:2-3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pneumonia

1992
A probable mechanism for hyperpigmentation by fotemustine.
    Dermatology (Basel, Switzerland), 1992, Volume: 185, Issue:1

    Topics: Antineoplastic Agents; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Pigmentation Disorders; Thioredoxin-Disulfide Reductase

1992
Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Cancer chemotherapy and pharmacology, 1991, Volume: 29, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Time Factors

1991
Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine.
    Cancer chemotherapy and pharmacology, 1991, Volume: 29, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Injections, Intralesional; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

1991
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
    Cancer research, 1991, Jan-15, Volume: 51, Issue:2

    Topics: Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Lymphocytes; Male; Melanoma; Methyltransferases; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds

1991
Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds

1991
Sensitivity and resistance in human metastatic melanoma to the new chloroethylnitrosourea anti-tumor drug Fotemustine.
    Biochimica et biophysica acta, 1991, Jun-05, Volume: 1096, Issue:4

    Topics: Antineoplastic Agents; Cell Membrane; Chromatography, High Pressure Liquid; Drug Resistance; Glutathione Reductase; Humans; Kinetics; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Thioredoxin-Disulfide Reductase

1991
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathologie-biologie, 1990, Volume: 38, Issue:8

    Topics: Antineoplastic Agents; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

1990
In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
    Cancer chemotherapy and pharmacology, 1990, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Carmustine; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Thymidine; Tumor Cells, Cultured

1990
[Study of the clinical pharmacokinetics of fotemustine in various tumor indications].
    Bulletin du cancer, 1989, Volume: 76, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds

1989
Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma.
    Journal of the National Cancer Institute, 1988, Nov-02, Volume: 80, Issue:17

    Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

1988